Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
Halozyme Therapeutics (HALO) stock is nearing a buy point out of a long consolidation, but an alternate entry has emerged within its base. This leading biopharmaceutical company has developed a specialized drug delivery technology used by companies including Roche (RHHBY) and Bristol Myers Squibb (BMY). The IBD 50 name has a three-year sales growth rate of 32%, according to IBD…
